ideology-health
  • Our Solutions
  • About Us
    • ideology-health
    Privacy Policy
    Terms of Service
    Inc. 5000

    IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

    © 2026 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.

    Dr. Joshua Reuss discusses the design of the BEAMION Lung trial of zongertinib in HER2m NSCLC (Video 1/3)
    Sign up to watch this video

    Free access to all Sound Bites content

    Dr. Joshua Reuss discusses the design of the BEAMION Lung trial of zongertinib in HER2m NSCLC (Video 1/3)

    Published Apr 28, 2026

    J

    Joshua Reuss, MD

    Medical Professional

    BEAMION efficacy

    More in this series: BEAMION 1L Lung_2026
    Dr. Joshua Reuss reviews additional efficacy endpoints in treatment naïve population from the BEAMION trial of zongertinib in HER2m NSCLC (Video 2/3)

    Dr. Joshua Reuss reviews additional efficacy endpoints in treatment naïve population from the BEAMION trial of zongertinib in HER2m NSCLC (Video 2/3)

    BEAMION secondary efficacy

    Joshua Reuss, MD
    Lung Cancer
    Dr. Joshua Reuss describes the safety of zongertinib in patients with HER2mutated advanced lung cancer (Video 3/3)

    Dr. Joshua Reuss describes the safety of zongertinib in patients with HER2mutated advanced lung cancer (Video 3/3)

    BEAMION safety

    Joshua Reuss, MD
    Lung Cancer
    Related Videos
    Dr. Gabriela Hobbs discusses event-free survival outcomes with ropeginterferon in polycythemia vera (Video 3/3)

    Dr. Gabriela Hobbs discusses event-free survival outcomes with ropeginterferon in polycythemia vera (Video 3/3)

    Gabriela Hobbs, MD
    Dr. Eytan Stein explores how emerging clinical data and real-world experience are shaping the treatment landscape in AML (Video 3/3)

    Dr. Eytan Stein explores how emerging clinical data and real-world experience are shaping the treatment landscape in AML (Video 3/3)

    Eytan Stein, MD
    Dr. Wade Iams reviews the efficacy of dose interruption/reduction strategies for patients with EGFRm mNSCLC on 1L amivantamab + lazertinib (Video 2/3)

    Dr. Wade Iams reviews the efficacy of dose interruption/reduction strategies for patients with EGFRm mNSCLC on 1L amivantamab + lazertinib (Video 2/3)

    Wade Iams, MD
    What sets iberdomide apart from established IMiDs? Dr. Rahul Banerjee explains. (Video 1/3)

    What sets iberdomide apart from established IMiDs? Dr. Rahul Banerjee explains. (Video 1/3)

    Rahul Banerjee, MD
    Dr. Gabriela Hobbs examines how ropeginterferon moves beyond disease control toward disease modification in the treatment of polycythemia vera. (Video 2/3)

    Dr. Gabriela Hobbs examines how ropeginterferon moves beyond disease control toward disease modification in the treatment of polycythemia vera. (Video 2/3)

    Gabriela Hobbs, MD
    Dr. Eytan Stein reviews the patient impact of treating AML at the first opportunity versus waiting for mutational testing (Video 2/3)

    Dr. Eytan Stein reviews the patient impact of treating AML at the first opportunity versus waiting for mutational testing (Video 2/3)

    Eytan Stein, MD